Escalier Biosciences
Norman serves on the board of directors of Infinity Pharmaceuticals, Inc., Merz GmbH & Co. KGaA, Metamark Genetics, Inc., National Parks Conservation Association, Ralph Lauren Center, Ulthera, Inc., Memorial Sloan-Kettering Cancer Center, and Central Park Conservancy, Inc. Norman was previously a Senior Advisor with Perseus LLC, Chairman of Windhover Information, Inc., President & Chief Executive Officer of TransForm Pharmaceuticals, Inc., Executive Vice President of Citicorp, Inc., Chief Operating Officer of New York Blood Center, Inc., Director & Senior Partner of McKinsey & Co., Inc., and Chief Executive Officer of Reimbursement Intelligence. He has also served on the board at Ascenta Therapeutics, Inc., Physicians Interactive Holdings LLC, NanoBio Corp., Millennium Pharmaceuticals, Inc., BioForm Medical, Inc., KEW Group, Inc., and Physicians Interactive, Inc. Norman received a B.A. in Architecture from Yale College and an M.B.A. with Distinction from the Harvard Business School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Escalier Biosciences
Escalier Biosciences is developing both topical and oral RORγt inverse agonists for the treatment of a broad spectrum of psoriasis patients – from the underserved mild-to-moderate patients that would benefit from a safe and effective topical RORγt therapeutic to the more moderate-to-severe patients that would benefit from a safe and effective oral RORγt drug in lieu of injectable biologic therapies targeting IL-17 and IL-23.